Symposium
Immuno-Oncology: Advances in Translating from Bench to Clinic
Speakers:
Luis Borges, Deborah Charych, Ravi Majeti, Brian Wong, Juan Jaen, Tara Arvedson, Jason DeVoss, Lelia Delamarre, Cheng Liu
Organizers:
Snow Ge (Nektar), Deborah Charych (Nektar), Wenfeng Xu (Genentech)
Date:
2017-06-28
Time:
8:45-17:00 Pacific Time
Registration fee:
(USD): Regular: $195; Academic: $125; Students & Unemployed: $35
Location:
Crowne Plaza, Foster City, CA
Major Sponsor:
Vendor show vendors registered to date:
(23)Applied BioMath; Aragen Bioscience, Inc.; BioLegend; Bio-Techne; Cardinal Health; Cellular Dynamics Intl; Covance; CrownBio; Cytovier LLC; Eurofins; Eurofins Discovery; Fujifilm Diosynth Biotechnologies; Intertek; PeproTech Inc; PharmaLegacy; PHARMout Laboratories; PPD; Premier Research; Quintara Discovery (QDI); Science Exchange; Second Genome; ThermoFisher; WuXi Apptec
Registration: http://www.PBSS.org
Registration deadline:2017-06-27
(it will close sooner if the seating cap is reached)
About the Topic
8:45-8:55 Opening Remarks and Introduction
8:55-9:35 Discovery of new drug targets and therapeutic approaches for cancer immunotherapy (Luis Borges, SVP, Five Prime Therapeutics)
9:35-10:15 Harnessing the Potent IL2 Immune Stimulatory Pathway with Designer Polymers (Deborah Charych, ED, Nektar)
10:15-10:25 Major sponsor presentation (Charles River)
10:25-10:40 Break
10:40-11:20 Pre-Clinical Development of a Humanized Anti-CD47 Antibody (Ravi Majeti, Professor, Stanford)
11:20-12:00 Discovery and development of orally-available cancer immunotherapies (Brian Wong, CEO, FLX Bio)
12:00-1:00 Lunch
1:00-1:40 Small Molecules, Antibodies, and Cell-based Therapies in the Fight Against Cancer (Juan Jaen, Founder and President, Arcus Biosciences and PACT Pharma)
1:40-2:20 Blincyto and BiTE® Antibody Platform for Cancer Therapy (Tara Arvedson, Principal Scientist, Amgen)
2:20-2:30 Major sponsor presentation (Celerion)
2:30-2:45 Break
2:45-3:25 T-VEC and oncolytic therapy (Jason DeVoss, Sr. Scientist, Amgen)
3:25-4:05 Personalized Cancer Vaccine (Lelia Delamarre, Sr. Scientist, Genentech)
4:05-4:15 Break
4:15-4:55 After CD19: CAR-T for solid tumor (Cheng Liu, CEO, Eureka)
4:55-5:15 General Q&A
2024-09-20, [In-Person] Nonclinical Safety Assessments of Biologics and Other Novel Modalities for IND/NDA/BLA Filings
|
2024-09-25, [Free Online] Development of Protein Degraders: Computational Modeling, Medicinal Chemistry and Early Development
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
2024-10-25, [Free Online Workshop] Unleashing the Power of Real-World Evidence / Data (RWE/RWD) to Facilitate Drug Discovery, Development, and Beyond
|
2024-11-01, [In-Person] Clinical Pharmacology Studies on Hepatic and Renal Impairments for NDA Filing: Strategies, Design, Conduct, Analysis and Regulatory Aspects
|
2024-11-13, [Free Online Workshop] Career Transition for Research Scientists: Business Development & BioPartnering
|
2024-11-15, [In-Person] Current State of Bioanalysis for Biologics and Cell/Gene Therapy Products: Refining Established Approaches for New Complex Therapies
|
2024-12-05, [Free Online] Innovative Mass Spectrometry and Related Technologies for Life Science and Drug Development
|
2024-12-13, Why All These New Modalities?
|
2025-01-22, [In-Person] Small-Molecule Formulation for Discovery & Early Development (jointly by PBSS / AAPS-BADG / Syner-G)
|
2025-02-06, [In-Person] Intellectual Property (IP) Strategies and Best Practices
|